mAbxience | Our story: moving forward

Our story:
moving forward


  • Established in Europe
  • Start of R&D activities

  • Acquisition and start of construction of pharmADN (mAbxience Buenos Aires plant)

  • mAbxience Buenos Aires plant: inauguration
  • GMP certification granted for mAbxience Buenos Aires facility through successful ANMAT inspection
  • First industrial batch
  • First clinical trial recruitment (rituximab)

  • Clinical trial recruitment (bevacizumab)

  • Genhelix biopharmaceutical plant acquisition (León, Spain)
  • Novex® (rituximab) launch in Argentina

  • mAbxience León plant: inauguration

  • Bevax® (bevacizumab) launch in Argentina
  • Project with WHO and UCAB to develop Palivizumab biosimilar
  • Biosimilar Initiative of the Year Award 2016 by Generics Bulletin

  • European GMP certification granted for mAbxience León facility, through successful AEMPS inspection
  • Initiation of project for the construction of a new monoclonal antibodies manufacturing plant in Buenos Aires
  • Expansion of global access of rituximab
  • Scientific Advices with the EMA and the FDA
  • Clinical trials of rituximab and bevacizumab completed

  • GMP certification to mAbxience León following the successful inspection by the Turkish Medicines And Medical Devices Agency
  • Business Development of the Year Award 2018 by Generics Bulletin

ANMAT: National Administration of Drugs, Foods and Medical Devices.

WHO: World Health Organization

UCAB: Utrecht Centre for Affordable Biotherapeutics

GMP: Good Manufacturing Practices

AEMPS: Spanish Agency for Medicines and Medical Devices

EMA: European Medicines Agency

FDA: Food Drug Administration